New England Journal of Medicine· 2017Q1

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich et al.

1,267citations
Q1SCImago
2017year

Short summary

After nearly 11 years of follow-up, imatinib treatment for chronic myeloid leukemia (CML) demonstrated sustained efficacy and an acceptable safety profile, with an 83.3% overall survival rate.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine